CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Hyperphosphorylated tau protein (P-tau) in CSF is a core biomarker candidate of Alzheimer's disease. Hyperphosphorylation of tau is thought to lead to neurofibrillary changes, a neuropathological hallmark of this type of dementia. Currently, the question is unresolved whether CSF levels of P-tau reflect neurofibrillary changes within the brain of a patient with the illness. Twenty-six patients were included with intra-vitam CSF as well as post-mortem neuropathological data. In the CSF, P-tau phosphorylated at threonine 231 (P-tau231P) was analysed. Post-mortem, scores of neurofibrillary tangles (NFT) and neuritic plaques (NP) were assessed in frontal, temporal, parietal and hippocampal cortical areas. In the same cortical regions, load of hyperphosphorylated tau protein (HP-tau load) was determined. Concentrations of P-tau231P were measured in frontal cortex homogenates. We found significant correlations between CSF P-tau231P concentrations and scores of NFTs and HP-tau load in all neocortical regions studied. The score of NPs was correlated with CSF P-tau231P only within the frontal cortex. There was a correlation between P-tau231P in CSF and brain homogenates. These findings indicate that CSF P-tau231P may serve as an in vivo surrogate biomarker of neurofibrillary pathology in Alzheimer's disease.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
From NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease (2018) · cites this paper as [81]
In the citing paper
“but correlations between in vivo CSF tau biomarkers and tau aggregates in postmortem tissue are weaker (11).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [11]
In the citing paper
“levels of CSF tau and phosphorylated tau (ptau) species are elevated in DAT8, 13, 14 and are hypothesized to reflect the presence of neurofibrillary tangles and/or neurodegeneration,15, 16 although not all studies support this conclusion.17”
From Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly (2009) · cites this paper as [16]
Citations
Cites
Efron, B., & Tibshirani, R. (1986) · Statistical Science · doi:10.1214/ss/1177013815 · Cited by 6,033
Gauthier, S., Reisberg, B., Zaudig, M., Petersen, R. C., Ritchie, K., Broich, K., Belleville, S., Brodaty, H., Bennett, D., Chertkow, H., et al. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68542-5 · Cited by 3,850
Self-citationGrundke-Iqbal, I., Iqbal, K., Tung, Y. C., Quinlan, M., Wisniewski, H. M., & Binder, L. I. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.13.4913 · Cited by 3,676
Braak, H., Alafuzoff, I., Arzberger, T., Kretzschmar, H., & Del Tredici, K. (2006) · Acta Neuropathologica · doi:10.1007/s00401-006-0127-z · Cited by 3,172 · cited 2×
“A staging system of Alzheimer’s-associated neurofibrillary pathology using immunohistochemistry and AT8 has been suggested (Braak et al., 2006).”
BackgroundMethodSelf-citationHYMAN, B. T., & TROJANOWSKI, J. Q. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199710000-00002 · Cited by 1,542
A68: a Major Subunit of Paired Helical Filaments and Derivatized Forms of Normal Tau
Lee, V. M.-Y., Balin, B. J., Otvos, L., & Trojanowski, J. Q. (1991) · Science · doi:10.1126/science.1899488 · Cited by 1,418 · cited 2×
“Whereas NFTs and neuritic processes are composed of fibrils containing phosphorylated tau, plaques consist mostly of fibrillous beta-amyloid (Grundke-Iqbal et al., 1986; Lee et al., 1991; Dickson, 1997).”
BackgroundCSF markers for incipient Alzheimer's disease
Blennow, K., & Hampel, H. (2003) · The Lancet Neurology · doi:10.1016/s1474-4422(03)00530-1 · Cited by 1,291 · cited 4×
“CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease Katharina Buerger,1,* Michael Ewers,1,* Tuula Pirttilä,2 Raymond Zinkowski,4 Irina Alafuzoff,3 Stefan J. Teipel,1 John DeBernardis,4 Daniel Kerkman,4 Cheryl McCulloch,4 Hilkka Soininen2 and Harald Hampel1 1Deme…”
BackgroundMethodResultInfluentialSelf-citationConsensus Recommendations for the Postmortem Diagnosis of Alzheimer’s Disease
(1997) · Neurobiology of Aging · doi:10.1016/s0197-4580(97)00057-2 · Cited by 981
Mandelkow, E. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01368-3 · Cited by 953
The Pathogenesis of Senile Plaques
DICKSON, D. W. (1997) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/00005072-199704000-00001 · Cited by 753
Cited by
NIA‐AA Research Framework: Toward a biological definition of Alzheimer's disease
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Dunn, B., Haeberlein, S. B., Holtzman, D. M., Jagust, W., Jessen, F., Karlawish, J., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.018 · Cited by 10,537
“The level of CSF P-tau also does correlate with severity of PHF tau accumulation after death [81,150].”
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Jack, C. R., Knopman, D. S., Jagust, W. J., Petersen, R. C., Weiner, M. W., Aisen, P. S., Shaw, L. M., Vemuri, P., Wiste, H. J., Weigand, S. D., et al. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70291-0 · Cited by 4,396
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
2018 Alzheimer's disease facts and figures
Alzheimer's Association (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.02.001 · Cited by 1,912
Preclinical Alzheimer’s Disease: Definition, Natural History, and Diagnostic Criteria
Dubois, B., Hampel, H., Feldman, H. H., Scheltens, P., Aisen, P., Andrieu, S., Bakardjian, H., Benali, H., Bertram, L., Blennow, K., et al. (2016) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.02.002 · Cited by 1,925
“This suggests that in AD, CSF tau changes may not only be considered as nonspecific (downstream) markers of neuronal death, as seen in other neurodegenerative diseases [60], but also as a more-specific pathophysiological marker of AD in relation to neurofibrillary tangles [61,62].”
BackgroundSelf-citationRevising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Self-citationA/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Jack, C. R., Bennett, D. A., Blennow, K., Carrillo, M. C., Feldman, H. H., Frisoni, G. B., Hampel, H., Jagust, W. J., Johnson, K. A., Knopman, D. S., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002923 · Cited by 1,864
Self-citationCerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationMasters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Role of neuroinflammation in neurodegeneration development
Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668
“In line with these results, many studies have suggested that both the total tau and phosphorylated tau are increased in the CSF of R47H carrying AD patients compared with non-carriers,(202) and the increasing of tau in CSF can be attributed to the pathology burden of tau in the brain.(203) In addition, TREM2 deficienc…”
ResultProbing sporadic and familial Alzheimer’s disease using induced pluripotent stem cells
Israel, M. A., Yuan, S. H., Bardy, C., Reyna, S. M., Mu, Y., Herrera, C., Hefferan, M. P., Van Gorp, S., Nazor, K. L., Boscolo, F. S., et al. (2012) · Nature · doi:10.1038/nature10821 · Cited by 1,253
Alzheimer disease: Epidemiology, diagnostic criteria, risk factors and biomarkers
Reitz, C., & Mayeux, R. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.12.024 · Cited by 1,181
Epidemiology of Alzheimer Disease
Mayeux, R., & Stern, Y. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006239 · Cited by 1,064
Biomarkers for Alzheimer's disease: current status and prospects for the future
Blennow, K., & Zetterberg, H. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12816 · Cited by 1,000
Biomarker Modeling of Alzheimer’s Disease
Jack, C. R., & Holtzman, D. M. (2013) · Neuron · doi:10.1016/j.neuron.2013.12.003 · Cited by 1,002
Tau phosphorylation: the therapeutic challenge for neurodegenerative disease
Hanger, D. P., Anderton, B. H., & Noble, W. (2009) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2009.01.003 · Cited by 965
“The concentration of phosphorylated T231 in cerebrospinal fluid is associated with increased neurofibrillary tangle load in AD, and a deficit in Pin1 results in neurodegeneration, together indicating that phosphorylation at this residue might be significant in AD pathogenesis[ 12 ].”
BackgroundTapiola, T., Alafuzoff, I., Herukka, S.-K., Parkkinen, L., Hartikainen, P., Soininen, H., & Pirttilä, T. (2009) · Archives of Neurology · doi:10.1001/archneurol.2008.596 · Cited by 896
Self-citationAdvancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0762-2 · Cited by 761
the Dominantly Inherited Alzheimer Network, Barthélemy, N. R., Li, Y., Joseph-Mathurin, N., Gordon, B. A., Hassenstab, J., Benzinger, T. L. S., Buckles, V., Fagan, A. M., Perrin, R. J., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0781-z · Cited by 651
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives
Hampel, H., Frank, R., Broich, K., Teipel, S. J., Katz, R. G., Hardy, J., Herholz, K., Bokde, A. L. W., Jessen, F., Hoessler, Y. C., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3115 · Cited by 631
Self-citationVisser, P. J., Verhey, F., Knol, D. L., Scheltens, P., Wahlund, L.-O., Freund-Levi, Y., Tsolaki, M., Minthon, L., Wallin, Å. K., Hampel, H., et al. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70139-5 · Cited by 614
Self-citationThe Neuropathology of Chronic Traumatic Encephalopathy
McKee, A. C., Stein, T. D., Kiernan, P. T., & Alvarez, V. E. (2015) · Brain Pathology · doi:10.1111/bpa.12248 · Cited by 585
“Although there are no validated imaging techniques or biomarkers to confirm the diagnosis of CTE in living subjects, potentially useful imaging and biomarkers include positron emission tomography (PET) ligands for p-tau and neuroinflammation (13, 64), diffusion tensor imaging (4, 50), magnetic resonance spectroscopy (…”
BackgroundHansson, O., Lehmann, S., Otto, M., Zetterberg, H., & Lewczuk, P. (2019) · Alzheimer's Research & Therapy · doi:10.1186/s13195-019-0485-0 · Cited by 585
Core candidate neurochemical and imaging biomarkers of Alzheimer's disease
Hampel, H., Bürger, K., Teipel, S. J., Bokde, A. L. W., Zetterberg, H., & Blennow, K. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.08.006 · Cited by 532
Self-citationNew insights into the role of TREM2 in Alzheimer’s disease
Gratuze, M., Leyns, C. E. G., & Holtzman, D. M. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0298-9 · Cited by 489
The role of tau in neurodegeneration
Gendron, T. F., & Petrucelli, L. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-13 · Cited by 478
“Elevated levels of hyperphosphorylated tau are also detected in cerebral spinal fluid of AD patients and may be predictive of neurodegeneration [92,93].”
Clinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Self-citationCerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease
Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15436-0 · Cited by 450
De-Paula, V. J., Radanovic, M., Diniz, B. S., & Forlenza, O. V. (2012) · Subcellular Biochemistry · doi:10.1007/978-94-007-5416-4_14 · Cited by 405
Longitudinal Change in CSF Biomarkers in Autosomal-Dominant Alzheimer’s Disease
Fagan, A. M., Xiong, C., Jasielec, M. S., Bateman, R. J., Goate, A. M., Benzinger, T. L. S., Ghetti, B., Martins, R. N., Masters, C. L., Mayeux, R., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007901 · Cited by 434
Thambisetty, M., Simmons, A., Velayudhan, L., Hye, A., Campbell, J., Zhang, Y., Wahlund, L.-O., Westman, E., Kinsey, A., Güntert, A., et al. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.78 · Cited by 405
Self-citationMRI and CSF biomarkers in normal, MCI, and AD subjects: Predicting future clinical change
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79fb · Cited by 396
Microtubule-associated protein tau in development, degeneration and protection of neurons
Wang, J.-Z., & Liu, F. (2008) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.03.002 · Cited by 398
Total and phosphorylated tau protein as biological markers of Alzheimer’s disease
Hampel, H., Blennow, K., Shaw, L. M., Hoessler, Y. C., Zetterberg, H., & Trojanowski, J. Q. (2010) · Experimental Gerontology · doi:10.1016/j.exger.2009.10.010 · Cited by 389
“, 2002a) and with neocortical NFT-pathology in AD (Buerger et al., 2006).”
BackgroundSelf-citationGWAS of Cerebrospinal Fluid Tau Levels Identifies Risk Variants for Alzheimer’s Disease
Cruchaga, C., Kauwe, J. S. K., Harari, O., Jin, S. C., Cai, Y., Karch, C. M., Benitez, B. A., Jeng, A. T., Skorupa, T., Carrell, D., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.026 · Cited by 383
“CSF ptau levels correlate with the number of neurofibrillary tangles and the load of hyperphosphorylated tau present in the brain (Buerger et al., 2006).”
BackgroundBrain PET in the Diagnosis of Alzheimer’s Disease
Marcus, C., Mena, E., & Subramaniam, R. M. (2014) · Clinical Nuclear Medicine · doi:10.1097/rlu.0000000000000547 · Cited by 382
Circulating miRNA Biomarkers for Alzheimer's Disease
Kumar, P., Dezso, Z., MacKenzie, C., Oestreicher, J., Agoulnik, S., Byrne, M., Bernier, F., Yanagimachi, M., Aoshima, K., & Oda, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0069807 · Cited by 381
Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease
Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Initiative, F. T. A. D. N., Minthon, L., Blennow, K., Olsson, M., For the Swedish BioFINDER study group, Hansson, O., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001991 · Cited by 375
“such as tau (a measure of neuronal degeneration(8)) and hyperphosphorylated tau (p-tau; a potential marker of tau pathology).(9) Several studies have examined the agreement between amyloid PET and CSF Ab42, but head-to-head studies comparing their diagnostic accuracy for incipient AD are scarce.”
BackgroundReduced non–rapid eye movement sleep is associated with tau pathology in early Alzheimer’s disease
Lucey, B. P., McCullough, A., Landsness, E. C., Toedebusch, C. D., McLeland, J. S., Zaza, A. M., Fagan, A. M., McCue, L., Xiong, C., Morris, J. C., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau6550 · Cited by 362
Li, J.-Q., Tan, L., Wang, H.-F., Tan, M.-S., Tan, L., Xu, W., Zhao, Q.-F., Wang, J., Jiang, T., & Yu, J.-T. (2016) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-310095 · Cited by 359
Mendez, M. F. (2017) · Neurologic Clinics · doi:10.1016/j.ncl.2017.01.005 · Cited by 356
Mattsson-Carlgren, N., Andersson, E., Janelidze, S., Ossenkoppele, R., Insel, P., Strandberg, O., Zetterberg, H., Rosen, H. J., Rabinovici, G., Chai, X., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz2387 · Cited by 359
Blood‐based biomarkers for Alzheimer's disease
Leuzy, A., Mattsson‐Carlgren, N., Palmqvist, S., Janelidze, S., Dage, J. L., & Hansson, O. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114408 · Cited by 351
Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia
Ewers, M., Sperling, R. A., Klunk, W. E., Weiner, M. W., & Hampel, H. (2011) · Trends in Neurosciences · doi:10.1016/j.tins.2011.05.005 · Cited by 347
Self-citationAlzheimer's Disease and Mild Cognitive Impairment
Kelley, B. J., & Petersen, R. C. (2007) · Neurologic Clinics · doi:10.1016/j.ncl.2007.03.008 · Cited by 326
Decreased cerebrospinal fluid Aβ 42 correlates with brain atrophy in cognitively normal elderly
Fagan, A. M., Head, D., Shah, A. R., Marcus, D., Mintun, M., Morris, J. C., & Holtzman, D. M. (2009) · Annals of Neurology · doi:10.1002/ana.21559 · Cited by 327
Lewczuk, P., Riederer, P., O’Bryant, S. E., Verbeek, M. M., Dubois, B., Visser, P. J., Jellinger, K. A., Engelborghs, S., Ramirez, A., Parnetti, L., et al. (2018) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2017.1375556 · Cited by 307
Self-citationHampel, H. J., Ewers, M., Bürger, K., Annas, P., Mörtberg, A., Bogstedt, A., Frölich, L., Schröder, J., Schönknecht, P., Riepe, M. W., et al. (2009) · PubMed · Cited by 305
Self-citationIncreased cerebrospinal fluid soluble TREM2 concentration in Alzheimer’s disease
Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., Öhrfelt, A., Blennow, K., Hardy, J., Schott, J., et al. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0071-x · Cited by 303
Biochemistry of Tau in Alzheimer’s disease and related neurological disorders
Sergeant, N., Bretteville, A., Hamdane, M., Caillet-Boudin, M.-L., Grognet, P., Bombois, S., Blum, D., Delacourte, A., Pasquier, F., Vanmechelen, E., et al. (2008) · Expert Review of Proteomics · doi:10.1586/14789450.5.2.207 · Cited by 300
Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI
Initiative, T. A. D. N., Shaw, L. M., Vanderstichele, H., Knapik-Czajka, M., Figurski, M., Coart, E., Blennow, K., Soares, H., Simon, A. J., Lewczuk, P., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0808-0 · Cited by 298
Wang, L., Benzinger, T. L., Su, Y., Christensen, J., Friedrichsen, K., Aldea, P., McConathy, J., Cairns, N. J., Fagan, A. M., Morris, J. C., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2078 · Cited by 293
Shaw, L. M., Arias, J., Blennow, K., Galasko, D., Molinuevo, J. L., Salloway, S., Schindler, S., Carrillo, M. C., Hendrix, J. A., Ross, A., et al. (2018) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.220 · Cited by 266
“[59] Buerger K, Ewers M, Pirttila T, Zinkowski R, Alafuzoff I, Teipel SJ, et al.”
BackgroundDiagnosis of Alzheimer’s disease utilizing amyloid and tau as fluid biomarkers
Lee, J. C., Kim, S. J., Hong, S., & Kim, Y. (2019) · Experimental & Molecular Medicine · doi:10.1038/s12276-019-0250-2 · Cited by 253
Impact of TREM2R47H variant on tau pathology–induced gliosis and neurodegeneration
Gratuze, M., Leyns, C. E. G., Sauerbeck, A. D., St-Pierre, M.-K., Xiong, M., Kim, N., Serrano, J. R., Tremblay, M.-È., Kummer, T. T., Colonna, M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci138179 · Cited by 252
Vemuri, P., Wiste, H. J., Weigand, S. D., Shaw, L. M., Trojanowski, J. Q., Weiner, M. W., Knopman, D. S., Petersen, R. C., & Jack, C. R. (2009) · Neurology · doi:10.1212/wnl.0b013e3181af79e5 · Cited by 246
Neely, A., Perry, C., Varisli, B., Singh, A. K., Arbneshi, T., Senapati, D., Kalluri, J. R., & Ray, P. C. (2009) · ACS Nano · doi:10.1021/nn900813b · Cited by 244
Advances in the development of new biomarkers for Alzheimer’s disease
Klyucherev, T. O., Olszewski, P., Shalimova, A. A., Chubarev, V. N., Tarasov, V. V., Attwood, M. M., Syvänen, S., & Schiöth, H. B. (2022) · Translational Neurodegeneration · doi:10.1186/s40035-022-00296-z · Cited by 241
“The specificity of this biomarker is supported by the fact that increased levels of P-Tau in CSF reflect the formation of neurofibrillary tangles in the brain [75].”
BackgroundAlzheimer neurofibrillary degeneration: significance, etiopathogenesis, therapeutics and prevention
Iqbal, K., & Grundke‐Iqbal, I. (2008) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2008.00225.x · Cited by 238
CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
Seppälä, T. T., Nerg, O., Koivisto, A. M., Rummukainen, J., Puli, L., Zetterberg, H., Pyykkö, O. T., Helisalmi, S., Alafuzoff, I., Hiltunen, M., et al. (2012) · Neurology · doi:10.1212/wnl.0b013e3182563bd0 · Cited by 236
Self-citationCurrent and Emerging Drug Treatment Options for Alzheimerʼs Disease: A Systematic Review
Herrmann, N., Chau, S. A., Kircanski, I., & Lanctôt, K. L. (2011) · Drugs · doi:10.2165/11595870-000000000-00000 · Cited by 237
Zetterberg, H. (2012) · Archives of Neurology · doi:10.1001/archneurol.2012.90 · Cited by 234
Molecular biomarkers of Alzheimer's disease: progress and prospects
Lashley, T., Schott, J. M., Weston, P., Murray, C. E., Wellington, H., Keshavan, A., Foti, S. C., Foiani, M., Toombs, J., Rohrer, J. D., et al. (2018) · Disease Models & Mechanisms · doi:10.1242/dmm.031781 · Cited by 230
Schöll, M., Maass, A., Mattsson, N., Ashton, N. J., Blennow, K., Zetterberg, H., & Jagust, W. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2018.12.001 · Cited by 229
Evidence for Ordering of Alzheimer Disease Biomarkers
Jack, C. R. (2011) · Archives of Neurology · doi:10.1001/archneurol.2011.183 · Cited by 223
Alves, G., Bronnick, K., Aarsland, D., Blennow, K., Zetterberg, H., Ballard, C., Kurz, M. W., Andreasson, U., Tysnes, O.-B., Larsen, J. P., et al. (2010) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2009.199950 · Cited by 221
Amlien, I. K., & Fjell, A. M. (2014) · Neuroscience · doi:10.1016/j.neuroscience.2014.02.017 · Cited by 219
CSF biomarkers in frontotemporal lobar degeneration with known pathology
Bian, H., Van Swieten, J. C., Leight, S., Massimo, L., Wood, E., Forman, M., Moore, P., de Koning, I., Clark, C. M., Rosso, S., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000311445.21321.fc · Cited by 216
Cerebrospinal fluid tau and amyloid-β1-42in patients with dementia
Skillbäck, T., Farahmand, B. Y., Rosén, C., Mattsson, N., Nägga, K., Kilander, L., Religa, D., Wimo, A., Winblad, B., Schott, J. M., et al. (2015) · Brain · doi:10.1093/brain/awv181 · Cited by 217
Safiri, S., Ghaffari Jolfayi, A., Fazlollahi, A., Morsali, S., Sarkesh, A., Daei Sorkhabi, A., Golabi, B., Aletaha, R., Motlagh Asghari, K., Hamidi, S., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1474043 · Cited by 200
Fluid biomarkers in Alzheimer’s disease – current concepts
Rosén, C., Hansson, O., Blennow, K., & Zetterberg, H. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-20 · Cited by 214
Fluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“Positive correlations between CSF levels of P-tau181 and P-tau231 (tau phosphorylated at residues 181 and 231, respectively) and neocortical tangle pathology at autopsy have been reported (Buerger et al. 2006; Tapiola et al. 2009).”
BackgroundOxysterols as biomarkers in neurodegenerative diseases
Leoni, V., & Caccia, C. (2011) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2011.04.002 · Cited by 212
TREM2, microglia, and Alzheimer’s disease.
Qin, Q., Teng, Z., Liu, C., Li, Q., Yin, Y., & Tang, Y. (2021) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2021.111438 · Cited by 219
Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play
Jack, C. R. (2012) · Radiology · doi:10.1148/radiol.12110433 · Cited by 211
Zhong, Z., Ewers, M., Teipel, S., Bürger, K., Wallin, A., Blennow, K., He, P., McAllister, C., Hampel, H., & Shen, Y. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.6.718 · Cited by 206
Self-citationAgreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse
Alcolea, D., Pegueroles, J., Muñoz, L., Camacho, V., López‐Mora, D., Fernández‐León, A., Le Bastard, N., Huyck, E., Nadal, A., Olmedo, V., et al. (2019) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.50873 · Cited by 183
Molinuevo, J. L., Blennow, K., Dubois, B., Engelborghs, S., Lewczuk, P., Perret‐Liaudet, A., Teunissen, C. E., & Parnetti, L. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.003 · Cited by 199
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease
Vemuri, P., Wiste, H. J., Weigand, S. D., Knopman, D. S., Shaw, L. M., Trojanowski, J. Q., Aisen, P. S., Weiner, M., Petersen, R. C., Jack, C. R., et al. (2010) · Annals of Neurology · doi:10.1002/ana.21953 · Cited by 195
“Increased CSF t-tau is a marker of neuronal injury, which correlates well with neurofibrillary tangle (NFT) stage and NFT load.(5,34) Our results indicate that t-tau does not significantly differ by APOE genotype among CN or AD, which is in agreement with a majority of CSF t-tau studies.”
Longitudinal stability of CSF biomarkers in Alzheimer's disease
Blennow, K., Zetterberg, H., Minthon, L., Lannfelt, L., Strid, S., Annas, P., Basun, H., & Andreasen, N. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2007.03.064 · Cited by 193
Saliva levels of Abeta1-42 as potential biomarker of Alzheimer's disease: a pilot study
Bermejo-Pareja, F., Antequera, D., Vargas, T., Molina, J. A., & Carro, E. (2010) · BMC Neurology · doi:10.1186/1471-2377-10-108 · Cited by 192
18F‐AV‐1451 and CSF T‐tau and P‐tau as biomarkers in Alzheimer's disease
Mattsson, N., Schöll, M., Strandberg, O., Smith, R., Palmqvist, S., Insel, P. S., Hägerström, D., Ohlsson, T., Zetterberg, H., Jögi, J., et al. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201707809 · Cited by 177
The pre-synaptic vesicle protein synaptotagmin is a novel biomarker for Alzheimer’s disease
Öhrfelt, A., Brinkmalm, A., Dumurgier, J., Brinkmalm, G., Hansson, O., Zetterberg, H., Bouaziz-Amar, E., Hugon, J., Paquet, C., & Blennow, K. (2016) · Alzheimer's Research & Therapy · doi:10.1186/s13195-016-0208-8 · Cited by 184
Woodruff, G., Young, J. E., Martinez, F. J., Buen, F., Gore, A., Kinaga, J., Li, Z., Yuan, S. H., Zhang, K., & Goldstein, L. S. B. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.018 · Cited by 177
Ashton, N. J., Leuzy, A., Lim, Y. M., Troakes, C., Hortobágyi, T., Höglund, K., Aarsland, D., Lovestone, S., Schöll, M., Blennow, K., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0649-3 · Cited by 172
“However, it remains unclear if CSF P-tau truly reflects NFT burden, with mixed findings having been reported for P-tau181(Buerger et al. 2007; Engelborghs et al. 2007; Seppala et al. 2012), though a positive association has been reported for P-tau231 (Buerger et al. 2006).”
BackgroundResultTau Proteolysis in the Pathogenesis of Tauopathies: Neurotoxic Fragments and Novel Biomarkers
Quinn, J. P., Corbett, N. J., Kellett, K. A. B., & Hooper, N. M. (2018) · Journal of Alzheimer's Disease · doi:10.3233/jad-170959 · Cited by 170
“Increased CSF concentrations of total tau (all tau isoforms independent of phosphorylation; including both full-length and fragmented species), as assessed by an ELISA [116], reflect AD neurodegeneration [reviewed by 117] while the presence or increase in phospho-tau (T181 and T231) reflects NFT build-up [118].”
Dissociating Normal Aging from Alzheimer’s Disease: A View from Cognitive Neuroscience
Toepper, M. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-161099 · Cited by 169
It's complicated: The relationship between sleep and Alzheimer's disease in humans
Lucey, B. P. (2020) · Neurobiology of Disease · doi:10.1016/j.nbd.2020.105031 · Cited by 168
Tau and p-tau as CSF biomarkers in dementia: a meta-analysis
van Harten, A. C., Kester, M. I., Visser, P.-J., Blankenstein, M. A., Pijnenburg, Y. A. L., van der Flier, W. M., & Scheltens, P. (2011) · cclm · doi:10.1515/cclm.2011.086 · Cited by 167
Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease: Current Evidence and Future Perspectives
McGrowder, D. A., Miller, F., Vaz, K., Nwokocha, C., Wilson-Clarke, C., Anderson-Cross, M., Brown, J., Anderson-Jackson, L., Williams, L., Latore, L., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11020215 · Cited by 167
Lattanzio, F., Abu-Rumeileh, S., Franceschini, A., Kai, H., Amore, G., Poggiolini, I., Rossi, M., Baiardi, S., McGuire, L., Ladogana, A., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1683-0 · Cited by 160
Spellman, D. S., Wildsmith, K. R., Honigberg, L. A., Tuefferd, M., Baker, D., Raghavan, N., Nairn, A. C., Croteau, P., Schirm, M., Allard, R., et al. (2015) · PROTEOMICS – Clinical Applications · doi:10.1002/prca.201400178 · Cited by 161
“To date, three CSF-based biomarkers of AD have been established with substantial international acceptance: decreases in A (cid:2) 42 and increases in total tau and phosphorylated tau181 (p-tau181, where p-tau is hyperphos-phorylatedtau)[9–17].”
CSF biomarkers predict rate of cognitive decline in Alzheimer disease
Kester, M. I., van der Vlies, A. E., Blankenstein, M. A., Pijnenburg, Y. A. L., van Elk, E. J., Scheltens, P., & van der Flier, W. M. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd8271 · Cited by 159
Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases
Lleó, A., Cavedo, E., Parnetti, L., Vanderstichele, H., Herukka, S. K., Andreasen, N., Ghidoni, R., Lewczuk, P., Jeromin, A., Winblad, B., et al. (2015) · Nature Reviews Neurology · doi:10.1038/nrneurol.2014.232 · Cited by 159
Review: Tau in biofluids – relation to pathology, imaging and clinical features
Zetterberg, H. (2017) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12378 · Cited by 157
Cedazo-Mínguez, Á., & Winblad, B. G. (2009) · Experimental Gerontology · doi:10.1016/j.exger.2009.09.008 · Cited by 181
Biomarkers used in Alzheimer’s disease diagnosis, treatment, and prevention
Mahaman, Y. A. R., Embaye, K. S., Huang, F., Li, L., Zhu, F., Wang, J.-Z., Liu, R., Feng, J., & Wang, X. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101544 · Cited by 149
Metadata
- Authors
- Buerger, K., Ewers, M., Pirttila, T., Zinkowski, R., Alafuzoff, I., Teipel, S. J., DeBernardis, J., Kerkman, D., McCulloch, C., Soininen, H., & Hampel, H.
- Affiliations
- Ludwig-Maximilians-Universität München (DE)
- Kuopio University Hospital (FI)
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09-29
- Volume
- 129
- Issue
- 11
- Pages
- 3035-3041
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2145450560
- Cited by
- 586
- References
- 33
- Citations by year
- 2026: 9 · 2025: 17 · 2024: 23 · 2023: 21 · 2022: 26 · 2021: 38 · 2020: 40 · 2019: 44 · 2018: 34 · 2017: 31 · 2016: 27 · 2015: 39 · 2014: 34 · 2013: 33 · 2012: 43
- FWCI
- 14.22
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Brain (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Cerebrospinal fluid and hydrocephalus
- Keywords
- Alzheimer's disease, tau phosphorylation, p-tau231, cerebrospinal fluid biomarkers, neurofibrillary tangles, neuritic plaques, neocortex, frontal cortex, hippocampus, postmortem neuropathology
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Female, Frontal Lobe, Hippocampus, Humans, Male, Parietal Lobe, Phosphorylation, Temporal Lobe, Biomarkers, Neurofibrillary Tangles, tau Proteins, Neocortex, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.